This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
NEEDHAM, Mass., Feb. 28, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will release fourth quarter and year end 2012 financial results on Thursday, March 7, 2013 before the U.S. financial markets open. Celldex executives will host a conference call at 8:30 a.m. ET on the same day to discuss 2012 financial and business results and to provide an update on key 2013 objectives.
The conference call and presentation will be webcast live over the Internet and can be accessed by logging on to the Events Calendar under the "News & Events" section of the Celldex Therapeutics website at
www.celldextherapeutics.com . The call can also be accessed by dialing 888-350-0137 (within the United States) or 970-315-0478 (outside the United States).
A replay of the call will be available approximately two hours after the live call concludes through March 21, 2013. To access the replay, dial 855-859-2056 (within the United States) or 404-537-3406 (outside the United States). The passcode is 13866763. The webcast will also be archived on the Company's website.
About Celldex Therapeutics, Inc.
Celldex Therapeutics is the first antibody-based combination immunotherapy company. Celldex has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused Precision Targeted Immunotherapy (PTI) Platform. The PTI Platform is a complementary portfolio of monoclonal antibodies, antibody-targeted therapeutics and immunomodulators used in optimal combinations to create novel disease-specific drug candidates. For more information, please visit
CONTACT: Sarah Cavanaugh
Vice President of Investor Relations &
Celldex Therapeutics, Inc.